Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trimetazidine dihydrochloride (Vastarel F) 是细胞保护性抗缺血剂,也用作缺血性心脏病或心绞痛的血管扩张剂,具有抗氧化,抗炎,抗伤害和胃保护作用。它可通过抑制脂肪酸代谢提高心肌葡萄糖利用率。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 313 | 现货 | ||
50 mg | ¥ 453 | 现货 | ||
100 mg | ¥ 659 | 现货 | ||
500 mg | ¥ 1,780 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 188 | 现货 |
产品描述 | Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina. |
靶点活性 | Long-chain 3-ketoacyl thiolase (mitochondrial):75 nM |
体外活性 | Trimetazidine通过上调miR-21表达靶向PTEN,增强PI3K通路的活性,抵抗缺氧/再灌注[3]的凋亡作用。 |
体内活性 | TMZ给药可减小WT C57BL/6J心脏的心肌梗塞面积。AMPK与ERK信号传导途径共同介导了TMZ对缺血性损伤的心脏保护作用。Trimetazidine转变新陈代谢从脂肪酸氧化向葡萄糖氧化,并在缺氧条件下改善心肌细胞的收缩功能[2]。 |
细胞实验 | The H9C2 cells are randomly assigned into three groups: Sham group, in which the cells are treated with 0μM TMZ for 48 h and then cultured under normal oxygenation conditions (5% CO2, and 95% air); H/R group, in which cells are treated with 0 μM TMZ for 48 h and then cultured under H/R conditions; and H/R+TMZ group, in which cells are treated with 10 μM TMZ for 48 h and then subjected to H/R treatment. (Only for Reference) |
别名 | 盐酸曲美他嗪, Yoshimilon, Kyurinett, Vastarel F |
分子量 | 339.258 |
分子式 | C14H24Cl2N2O3 |
CAS No. | 13171-25-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL (206.33 mM), Sonication and heating are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9476 mL | 14.738 mL | 29.4761 mL | 73.6902 mL |
5 mM | 0.5895 mL | 2.9476 mL | 5.8952 mL | 14.738 mL | |
10 mM | 0.2948 mL | 1.4738 mL | 2.9476 mL | 7.369 mL | |
20 mM | 0.1474 mL | 0.7369 mL | 1.4738 mL | 3.6845 mL | |
50 mM | 0.059 mL | 0.2948 mL | 0.5895 mL | 1.4738 mL | |
100 mM | 0.0295 mL | 0.1474 mL | 0.2948 mL | 0.7369 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Trimetazidine dihydrochloride 13171-25-0 Autophagy Metabolism Fatty Acid Synthase inhibit Trimetazidine Inhibitor 盐酸曲美他嗪 Trimetazidine Dihydrochloride Yoshimilon Kyurinett Vastarel F inhibitor